Matthew Shields - 05 Mar 2025 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
EVP, Global Operations
Signature
/s/ Dov Bergwerk as attorney-in-fact for Matthew Shields
Issuer symbol
TEVA
Transactions as of
05 Mar 2025
Net transactions value
$0
Form type
4
Filing time
07 Mar 2025, 16:10:16 UTC
Previous filing
05 Jun 2024
Next filing
05 Jun 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Award $0 +69,182 $0.000000 69,182 05 Mar 2025 Ordinary Shares 69,182 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F2 Restricted share units were granted on March 5, 2025, with 17,295 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 17,297 vesting on March 5, 2029.
F3 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.